Biotech news October 20, 2026: EVAX +23% reports durable EVX-01 benefit; BCDA +18% advances Helix De Novo review. BPC UPDATE 10/20/2026 ET TL;DR - Biotech movers: October 20, 2026. * Evaxion Biotech (EVAX): All six EVX-01 responders entering the third-year extension remained progression-free, reinforcing earlier Phase 2 melanoma results ahead of ESMO 2026. * BioCardia (BCDA): FDA accepted the updated Helix catheter De Novo pre-submission, with substantive review and an agency meeting expected this quarter. * Cumberland Pharmaceuticals (CPIX): Set October 26 for an ifetroban DMD-cardiomyopathy clinical update, creating a near-term pipeline catalyst. * Moleculin Biotech (MBRX): Completed Part A enrollment in Phase 2/3 MIRACLE, with 90-patient Annamycin plus HiDAC AML data targeted for Q1 2027. * INOVIO (INO): Won an $80.4M judgment against VGXI and GeneOne, although ultimate recovery remains uncertain given the defendants' financial condition. * Acumen Pharmaceuticals (ABOS): Scheduled its Q3 2026 financial and operational update for October 26, with no new clinical catalyst disclosed. * NanoViricides (NNVC): Juvenile mouse testing found no adverse effects with NV-387 at doses up to 3,690 mg/kg/day; human efficacy remains unproven. * Clene (CLNN) Filed an NDA seeking accelerated approval for CNM-Au8 in ALS, shifting focus to FDA acceptance and review. Biotech updates. Evaxion Biotech (NASDAQ: EVAX) announced that all six trial responders progressing into the third-year extension phase for EVX-01 sustained clinical benefits without disease progression under monotherapy administration. These long-term outcomes reinforce Phase 2 findings featuring a 75% objective response rate along with 25% complete responses, enhancing collaboration prospects prior to full presentation details at ESMO 2026. Shares closed up 23% at $4.08. BioCardia (NASDAQ: BCDA) reported that the FDA accepted its updated De Novo pre-submission filing for the Helix delivery catheter, scheduling a substantive review alongside a meeting with the agency during the current quarter. This progress supports possible independent medical device clearance, potentially opening additional partnership avenues with cellular, genetic, and protein-based therapeutic innovators seeking targeted transendocardial administration. Shares closed up 18% at $1.06. INOVIO Pharmaceuticals (NASDAQ: INO) won an $80.4 million legal judgment against VGXI and GeneOne Life Science over a breached DNA plasmid manufacturing agreement, securing $61.8 million in damages alongside $18.7 million in legal expenses and fees. While marking a favorable courtroom outcome, the defendants' financial status leaves full collection of the monetary award highly questionable. Shares are currently up 18% at $1.19 during extended hours. Acumen Pharmaceuticals (NASDAQ: ABOS) scheduled the release of its third-quarter 2026 financial and operational updates for October 26. Serving mainly as a corporate routine update for shareholders, the event includes no major therapeutic pipeline, regulatory, or capital updates. Shares closed up 14% at $2.02. Moleculin Biotech (NASDAQ: MBRX) highlighted operational progress in its Phase 2/3 MIRACLE study evaluating Annamycin combined with HiDAC for second-line relapsed or refractory AML, finishing Part A recruitment and targeting full 90-subject findings in Q1 2027. Serving mostly as routine investor relations communications, the update leaves the impending clinical efficacy data readout and potential transition to pivotal Part B as primary valuation drivers. Shares closed up 17% at $6.19. Cumberland Pharmaceuticals (NASDAQ: CPIX) scheduled the release of clinical progress updates for ifetroban in DMD-associated cardiomyopathy for October 26. Serving primarily as routine investor relations communications, the event leaves actual valuation shifts dependent on whether subsequent disclosures reveal substantive safety, efficacy, or pipeline milestones. Shares closed up 18% at $7.94. NanoViricides (NYSE: NNVC) announced positive juvenile mouse safety outcomes for NV-387, recording zero adverse effects at top doses up to 3,690 mg/kg daily. These preclinical findings reinforce ongoing pediatric strategy across measles, Mpox, and Ebola indications, though human therapeutic effectiveness has yet to be demonstrated. Shares closed up 14% at $1.48. Clene (NASDAQ: CLNN) filed an NDA seeking accelerated FDA clearance for CNM-Au8 to treat ALS, relying on clinical efficacy endpoints and neurofilament light chain biomarker findings. Representing a major regulatory milestone, the filing shifts focus to potential FDA acceptance and review, while Clene prepares its confirmatory Phase 3 RESTORE-ALS trial. Shares closed up 13% at $3.73.

CONROE, Texas, June 3, 2024 /PRNewswire/ -- VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, has entered into a strategic partnership with Sutro Biopharma, Inc. (Sutro) to support clinical production of luveltamab tazevibulin, abbreviated as "luvelta", a novel Folate Receptor-α (FRα)-targeting antibody-drug conjugate (ADC) with the potential to address the unmet need in several FRα-expressing cancers.Sutro, a clinical-stage oncology company pioneering site-specific and novel-format ADCs, has just initiated the randomized portion (Part 2) of REFRαME-O1, a global, registration-directed clinical trial of luvelta (NCT05870748) in platinum-resistant ovarian cancer (PROC). VGXI will supply cGMP plasmids at 1500L production scale for use in Sutro's XpressCF® cell-free expression system to manufacture luvelta. With evidence of clinical activity and the potential to benefit 8 out of 10 PROC patients, luvelta could address a high unmet medical need in patients with low to medium FRα expression."We are thrilled to establish this partnership to support the clinical production of luvelta and all of Sutro's ongoing projects," stated Young Park, CEO of VGXI. "Our expertise in large-scale cGMP plasmid production will be instrumental in advancing Sutro's promising therapy through its late-stage clinical trial evaluation and towards commercialization.""Our partnership with VGXI has been a cornerstone in our achievements to further enable our Cell Free manufacturing platform at commercial scale as our lead product candidate progresses to registrational clinical studies," commented Dr. Venkatesh Srinivasan, Chief Technical Operations Officer, Sutro Biopharma.As the demand for advanced therapies and targeted cancer treatments continues to grow, VGXI's state-of-the-art facilities and cutting-edge technologies enable the production of high-quality cGMP plasmid materials with the scale and speed necessary to bring these treatments to patients, now and into the future.ABOUT VGXI, INC.With over 20 years of experience VGXI, Inc